256 related articles for article (PubMed ID: 16307507)
1. Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.
Blanco JC; Boukhvalova MS; Hemming P; Ottolini MG; Prince GA
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):945-55. PubMed ID: 16307507
[TBL] [Abstract][Full Text] [Related]
2. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment.
Boukhvalova MS; Yim KC; Kuhn KH; Hemming JP; Prince GA; Porter DD; Blanco JC
J Infect Dis; 2007 Feb; 195(4):511-8. PubMed ID: 17230410
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Cardenas S; Auais A; Piedimonte G
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age.
El Saleeby CM; Somes GW; DeVincenzo JP; Gaur AH
Pediatrics; 2008 Feb; 121(2):235-43. PubMed ID: 18245413
[TBL] [Abstract][Full Text] [Related]
5. Infection by the respiratory syncytial virus in infants and young children at high risk.
Bonnet D; Schmaltz AA; Feltes TF
Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
[TBL] [Abstract][Full Text] [Related]
7. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
8. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study.
Bloemers BL; van Furth AM; Weijerman ME; Gemke RJ; Broers CJ; van den Ende K; Kimpen JL; Strengers JL; Bont LJ
Pediatrics; 2007 Oct; 120(4):e1076-81. PubMed ID: 17908728
[TBL] [Abstract][Full Text] [Related]
9. Treatment of respiratory syncytial virus: antiviral therapies.
Jafri HS
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S89-92; discussion S92-3. PubMed ID: 12671458
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus infections: characteristics and treatment.
Chidgey SM; Broadley KJ
J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
[TBL] [Abstract][Full Text] [Related]
11. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M
Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294
[TBL] [Abstract][Full Text] [Related]
12. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus infection in adults.
Falsey AR
Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771
[TBL] [Abstract][Full Text] [Related]
14. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations.
Feltes TF; Groothuis JR
Cardiol Young; 2005 Jun; 15(3):266-73. PubMed ID: 15865828
[TBL] [Abstract][Full Text] [Related]
15. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature.
Flynn JD; Akers WS; Jones M; Stevkovic N; Waid T; Mullett T; Jahania S
Pharmacotherapy; 2004 Jul; 24(7):932-8. PubMed ID: 15303457
[TBL] [Abstract][Full Text] [Related]
16. Acute encephalopathy associated with respiratory syncytial virus infections in childhood. A literature review.
Antonucci R; Fanos V
Minerva Pediatr; 2005 Jun; 57(3):137-42. PubMed ID: 16170298
[TBL] [Abstract][Full Text] [Related]
17. 2-5A antisense treatment of respiratory syncytial virus.
Leaman DW
Curr Opin Pharmacol; 2005 Oct; 5(5):502-7. PubMed ID: 16081320
[TBL] [Abstract][Full Text] [Related]
18. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention.
Rosenberg HF; Bonville CA; Easton AJ; Domachowske JB
Pharmacol Ther; 2005 Jan; 105(1):1-6. PubMed ID: 15626452
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide.
Dunn MC; Knight DA; Waldman WJ
Antivir Ther; 2011; 16(3):309-17. PubMed ID: 21555813
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
